Document Detail

Firstline treatment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy.
MedLine Citation:
PMID:  10921396     Owner:  NLM     Status:  MEDLINE    
In the initial treatment of chronic hepatitis C, interferon-alfa (IFN-alpha) monotherapy for 24-48 weeks induces sustained response rates of only 10-20%. Combination therapy with IFN-alpha plus ribavirin induces a sustained response in 40-50% of patients, and can be now recommended as the firstline therapy for chronic hepatitis C. Stopping therapy at week 12 because of persistent viraemia is unnecessary with the combination therapy because later clearance of HCV RNA can still occur with a sustained response. Patients with HCV genotype 1 should receive 48 weeks of combination therapy, in contrast to 24 weeks for patients with genotypes 2 or 3. For patients who cannot tolerate the side effects of ribavirin, such as anaemia, IFN-alpha at 3 MU three times weekly for 48 weeks is preferred as the initial therapy. The long-acting pegylated IFN can be expected to enhance the efficacy of combination therapy in the treatment of chronic hepatitis C and appears to be much more potent as monotherapy. Further studies are needed to improve the current 'half-full' status of chronic hepatitis C treatment.
M Y Lai
Related Documents :
16023976 - Use of growth factors with antiviral therapy for chronic hepatitis c.
18691426 - The prediction of interferon treatment effects based on time series microarray gene exp...
19841506 - Gilbert's syndrome and antiviral therapy of hepatitis c.
18397706 - Rapidly deteriorating renal function with membranoproliferative glomerulonephritis type...
25461736 - Insulin-resistance hcv infection-related affects vascular stiffness in normotensives.
12447726 - Assessing hepatitis b virus resistance in vitro and molecular mechanisms of nucleoside ...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of gastroenterology and hepatology     Volume:  15 Suppl     ISSN:  0815-9319     ISO Abbreviation:  J. Gastroenterol. Hepatol.     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-11-20     Completed Date:  2000-12-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8607909     Medline TA:  J Gastroenterol Hepatol     Country:  AUSTRALIA    
Other Details:
Languages:  eng     Pagination:  E130-3     Citation Subset:  IM    
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / administration & dosage*
Drug Administration Schedule
Drug Therapy, Combination
Hepatitis C, Chronic / drug therapy*,  virology
Interferon-alpha / administration & dosage*
Ribavirin / administration & dosage*
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 36791-04-5/Ribavirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Where does treatment fit into the strategy to control hepatitis C?
Next Document:  Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in ...